High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study

Published:2017-03-24 Issue:2 Volume:177 Page:263-270
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Nastoupil Loretta J.¹,McLaughlin Peter¹,Feng Lei²,Neelapu Sattva S.¹,Samaniego Felipe¹,Hagemeister Fredrick B.¹,Ayala Ana¹,Romaguera Jorge E.¹,Goy Andre H.¹³,Neal Eleanor¹,Wang Michael¹,Fayad Luis¹,Fanale Michelle A.¹,Oki Yasuhiro¹,Westin Jason R.¹^ORCID,Rodriguez Maria A.¹,Cabanillas Fernando¹⁴,Fowler Nathan H.¹

Affiliation:

1. Department of Lymphoma and Myeloma; The University of Texas M.D. Anderson Cancer Center; Houston TX USA

2. Department of Biostatistics; The University of Texas M.D. Anderson Cancer Center; Houston TX USA

3. John Theurer Cancer Center; Hackensack NJ USA

4. Auxilio Mutuo Cancer Center; San Juan PR USA

Funder

IC Design Education Center

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14541/fullpdf

Reference33 articles.

1. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival-A study from the groupe d'etude des lymphomes de l'adulte;Bachy;Journal of Clinical Oncology,2010

2. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome;Buske;Blood,2006

3. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;Journal of Clinical Oncology,1999

4. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi;Federico;Journal of Clinical Oncology,2013

5. Follicular lymphoma in the United States: first report of the national LymphoCare study;Friedberg;Journal of Clinical Oncology,2009

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding Functional Neurological Disorder: Recent Insights and Diagnostic Challenges;International Journal of Molecular Sciences;2024-04-18

2. Immunotherapy of Osteosarcoma;Handbook of Cancer and Immunology;2023

3. Glutathione-Mediated Conjugation of Anticancer Drugs: An Overview of Reaction Mechanisms and Biological Significance for Drug Detoxification and Bioactivation;Molecules;2022-08-17

4. An application of p-sulfonatocalix[6]arenes to attenuate cardiotoxicity of mitoxantrone in vitro: preparation, characterization and evaluation;Journal of Pharmacy and Pharmacology;2021-11-23

5. A single-center analysis of patients with extranodal marginal zone lymphoma of the breast;Leukemia & Lymphoma;2021-10-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3